LYEL Stock Overview
A clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Lyell Immunopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.76 |
52 Week High | US$3.97 |
52 Week Low | US$1.32 |
Beta | -0.55 |
1 Month Change | 14.52% |
3 Month Change | 13.11% |
1 Year Change | -4.50% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -83.66% |
Recent News & Updates
Recent updates
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Apr 16Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Feb 23Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Nov 09Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher
Aug 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Aug 11Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans
Dec 15Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845
Oct 06Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Sep 12News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts
Aug 08Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Apr 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
Sep 17Shareholder Returns
LYEL | US Biotechs | US Market | |
---|---|---|---|
7D | 5.7% | 0.7% | 1.2% |
1Y | -4.5% | 5.0% | 27.7% |
Return vs Industry: LYEL underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: LYEL underperformed the US Market which returned 27.7% over the past year.
Price Volatility
LYEL volatility | |
---|---|
LYEL Average Weekly Movement | 13.8% |
Biotechs Industry Average Movement | 11.2% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LYEL's share price has been volatile over the past 3 months.
Volatility Over Time: LYEL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 224 | Lynn Seely | lyell.com |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications.
Lyell Immunopharma, Inc. Fundamentals Summary
LYEL fundamental statistics | |
---|---|
Market cap | US$665.39m |
Earnings (TTM) | -US$228.34m |
Revenue (TTM) | US$68.00k |
Over9,999x
P/S Ratio-3.1x
P/E RatioIs LYEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LYEL income statement (TTM) | |
---|---|
Revenue | US$68.00k |
Cost of Revenue | US$0 |
Gross Profit | US$68.00k |
Other Expenses | US$228.41m |
Earnings | -US$228.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.90 |
Gross Margin | 100.00% |
Net Profit Margin | -335,794.12% |
Debt/Equity Ratio | 0% |
How did LYEL perform over the long term?
See historical performance and comparison